| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Neurotoxin Inhibitor targets neurotoxins, which are substances that are poisonous or destructive to nerve tissue. The specific molecular target of this compound has not been fully characterized, but it is classified as an inhibitor of neurotoxin activity. By blocking neurotoxin function, the compound may protect neurons from damage and degeneration.
|
|---|---|
| ln Vitro |
In vitro activity of Neurotoxin Inhibitor is characterized by its ability to inhibit neurotoxin activity. The compound is used in biochemical and cellular assays to assess its neuroprotective effects. Its activity is typically evaluated by measuring the reduction in neurotoxin-induced cell death or toxicity in neuronal cell cultures. Detailed IC₅₀ values have not been extensively reported.
|
| ln Vivo |
In vivo activity data for Neurotoxin Inhibitor are limited in the available literature. As a research tool, its primary application is in in vitro neuroscience studies to investigate neurotoxin mechanisms. The compound shows potential for studying neurodegenerative conditions, but systematic in vivo efficacy studies are lacking. Further research is needed to characterize its in vivo effects.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Neurotoxin Inhibitor are not extensively documented. As a neurotoxin inhibitor, its activity is typically assessed in cell-based models of neurotoxicity rather than cell-free enzyme assays. The compound's ability to protect neuronal cells from neurotoxin-induced damage is measured using viability assays and markers of cell death.
|
| Cell Assay |
In vitro cellular assays for Neurotoxin Inhibitor are performed using neuronal cell lines or primary neurons. Cells are treated with a neurotoxin in the presence and absence of the compound, and cell viability is assessed using MTT, LDH release, or other cytotoxicity assays. Neuroprotective effects are quantified by comparing cell death between treated and untreated groups.
|
| Animal Protocol |
In vivo animal experimental protocols for Neurotoxin Inhibitor are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models of neurodegenerative disease. The compound would be administered via appropriate routes, and neuroprotective efficacy would be assessed by behavioral tests, histological analysis, and biochemical markers of neurodegeneration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Neurotoxin Inhibitor have not been systematically characterized. The compound has a molecular weight of 346.41 and molecular formula C₁₉H₁₄N₄OS. It appears as a solid and should be stored as a powder at -20°C for up to 3 years. In solvent, it can be stored at -80°C for up to 1 year. It is shipped with blue ice.
|
| Toxicity/Toxicokinetics |
Toxicological data for Neurotoxin Inhibitor are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
Neurotoxin Inhibitor is a research compound with CAS number 951571-70-3, molecular formula C₁₉H₁₄N₄OS, and molecular weight 346.41. Its chemical name is 1-(1,3-benzothiazol-2-yl)-4-phenyl-1H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one. It is used in neuroscience research to study neurotoxin mechanisms and neuroprotective strategies. This product is for research use only.
|
| Molecular Formula |
C19H14N4OS
|
|---|---|
| Molecular Weight |
346.405662059784
|
| Exact Mass |
346.088
|
| CAS # |
951571-70-3
|
| PubChem CID |
135732862
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C(C2=C(NC1=O)N(N=C2)C3=NC4=CC=CC=C4S3)C5=CC=CC=C5
|
| InChi Key |
HLFQUUKVLVOMHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H14N4OS/c24-17-10-13(12-6-2-1-3-7-12)14-11-20-23(18(14)22-17)19-21-15-8-4-5-9-16(15)25-19/h1-9,11,13H,10H2,(H,22,24)
|
| Chemical Name |
1-(1,3-benzothiazol-2-yl)-4-phenyl-5,7-dihydro-4H-pyrazolo[3,4-b]pyridin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~45 mg/mL (~129.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (6.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.25 mg/mL (6.50 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.25 mg/mL (6.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8868 mL | 14.4338 mL | 28.8675 mL | |
| 5 mM | 0.5774 mL | 2.8868 mL | 5.7735 mL | |
| 10 mM | 0.2887 mL | 1.4434 mL | 2.8868 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
